Persistent Radiation-Induced Alopecia: Dose Dependence and Treatment
This retrospective cohort analysis sought to determine the association between pRIA and radiation dose and response to treatment.
This retrospective cohort analysis sought to determine the association between pRIA and radiation dose and response to treatment.
A survey found that dermatologists have more confidence in diagnosing, managing, and their personal knowledge of permanent chemotherapy-induced alopecia compared with clinicians who practice in oncology or primary care/internal medicine.
Entrepreneuring cancer survivors often use their experience as a catalyst to create unique products that solve the most challenging issues cancer patients face. Oncology Nurse Advisor presents five products designed by and for survivors.
A single-institution study is able to reproduce results of previous studies on the use of a scalp cooling system to prevent chemotherapy-induced hair loss in patients with breast cancer receiving anthracycline and/or taxane-based therapies.
A study results presented at the 2018 ONS Annual Congress demonstrated that incorporating scalp cooling with the Dignicap device prior to chemotherapy for breast cancer may reduce treatment-related alopecia.
The US FDA has granted expanded clearance for the DigniCap Cooling System to include use in patients undergoing chemotherapy for solid tumors in other areas of the body besides the breast.
Risk of chemotherapy-induced hair loss common to breast cancer therapy may be reduced with the use of scalp-cooling device.
A patient’s self image can reduce his or her coping abilities and can be significantly impacted by this distressing side effect.